|Table of Contents|

The clinical efficacy observation of oxycodone hydrochloride prolonged-release tablets combined with flupentixol and melitracentablets for terminal cancer-induced pain

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 04
Page:
609-612
Research Field:
Publishing date:

Info

Title:
The clinical efficacy observation of oxycodone hydrochloride prolonged-release tablets combined with flupentixol and melitracentablets for terminal cancer-induced pain
Author(s):
Bu Gang; Sun Xin; Wang Hui; Wang Suoliang
Department of Rehabilitation Medicine,The First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China.
Keywords:
cancer pain; oxycodone hydrochloride prolonged-release tablets; flupentixol and melitracen tablets
PACS:
R730.6
DOI:
10.3969/j.issn.1672-4992.2018.04.032
Abstract:
Objective:To evaluate the clinical efficacy of oxycodone hydrochloride prolonged-release tablets combined with flupentixol and melitracen tablets for advanced cancer-induced pain.Methods:We selected 80 cases of advanced cancer patients treated in our hospital from April 2013 to September 2015,they were randomly divided into observation group and control group,40 cases in each group.Patients in observation group received a combination of oxycodone hydrochloride prolonged-release tablets and flupentixol and melitracen tablets,patients in control group only received oxycodone hydrochloride prolonged-release tablets.After 1 months,the records of the two groups' degree of pain depression scale score,drug use dose and adverse reactions in the course of treatment were colleted and analyzed,comprehensively compared the clinical efficacy of the medicine in two groups.Results:There was no significant difference in NRS scores between the two groups before treatment (P>0.05).The scores of NRS in the two groups were significantly after decreased after treatment (P＜0.05),and compared with the control group,the NRS score of the observation group decreased more significantly.Similarly,the depression scale scores in two groups before treatment had no significant difference (P>0.05).After treatment,both the observation group and the control group of SDS and HRSD scores were significantly decreased (P＜0.05),what's more,the observation group decreased more significantly than the control group(P＜0.05),the average daily dose of the observation group is （45.62±5.17）mg/d,and the control group was (62.18±4.37) mg/d,the observation group was significantly lower than the control group(P＜ 0.05),but in the aspect of the incidence of adverse reactions,there is no significant difference between the two groups(P>0.05).Conclusion:The clinical efficacy of oxycodone hydrochloride prolonged-release tablets combined with flupentixol and melitracen tablets for terminal cancer-induced pain is significant.It can further lighten the pain in patients with anxiety and depression,and can reduce the dose of oxycodone hydrochloride prolonged-release tablets,it is worthy of popularization and application.

References:

［1］Yang P,Sun LQ,Lu Q,et al.Study on the quality of life and related factors of cancer pain patients［J］.China Nursing Management,2012,12 (2):25-28.［杨萍,孙丽秋,路潜,等.癌痛病人生活质量状况及其相关因素研究［J］.中国护理管理,2012,12(2):25-28.］
［2］Zhang TY,An B,Yang JL,et al.Investigation of depression in cancer pain patients and analysis of influencing factors［J］.Chinese Journal of Pain Medicine,2012,18(6):350-353.［张天燕,安波,杨娟丽,等.癌痛患者抑郁情绪的调查及影响因素分析［J］.中国疼痛医学杂志,2012,18(6):350-353.］
［3］Stepanski EJ,Walker MS,Schwartzberg LS,et al.The relation of trouble sleeping,depressed mood,pain,and fatigue in patients with cancer［J］.Journal of Clinical Sleep Medicine,2009,5(2):132-136.
［4］Li N,Yang BY,Wu XM,et al.Clinical observation of antidepressant drugs combined with opioids and psychological intervention in the treatment of advanced cancer pain accompanied by depression［J］.Chinese Cancer Clinic and Rehabilitation,2014,21(6):744-747.［李宁,杨渤彦,吴晓明,等.抗抑郁药物联合阿片类药物和心理干预治疗晚期癌痛伴抑郁的疗效观察［J］.中国肿瘤临床与康复,2014,21(6):744-747.］
［5］Bennett MI.Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain:Systematic review［J］.Palliative Medicine,2011,25(5):553.
［6］Kane CM,Mulvey MR,Wright S,et al.Opioids combined with antidepressants or antiepileptic drugs for cancer pain:Systematic review and meta-analysis［J］.Palliative Medicine,2017,3:269216317711826.
［7］Portenoy RK.Treatment of cancer pain［J］.Drug Evaluation,2012,377(9784):2236-2247.
［8］Caraceni A,Hanks G,Kaasa S,et al.Use of opioid analgesics in the treatment of cancer pain:Evidence-based recommendations from the EAPC［J］.Lancet Oncology,2012,13(2):e58.
［9］Mercadante S,Caraceni A.Conversion ratios for opioid switching in the treatment of cancer pain:A systematic review［J］.Palliative Medicine,2011,25(5):504-515.
［10］Vadalouca A,Raptis E,Moka E,et al.Pharmacological treatment of neuropathic cancer pain:A comprehensive review of the current literature［J］.Pain Practice,2012,12(3):219-251.
［11］Yi JQ,Wang XW,Liang JZ.Feasibility of oxycodone hydrochloride extended-release tablets in the titration of cancer pain［J］.Medical Innovation of China,2013,10(19):9-11.
［12］Ma Y,Zhao XB,Wu Z,et al.Observation of the curative effect of oxycodone hydrochloride prolonged-release tablets on the treatment of moderate to serious cancer pain［J］.Chinese Journal of Pharmacoepidemiology,2014,23(11):653-655.
［13］Tong GangLing,Wu Xuan,Jin Feng,et al.Clinical study of oxycodone hydrochloride prolonged-release tablets combined with immediate-release morphine tablets for titration treatment in moderate or severe cancer pain of patients［J］.Modern Oncology,2016,24(20):3267-3269.
［14］Liu N,Ma TJ,Zhang GY,et al.Clinical observation of oxycodone hydrochloride sustained release tablets in the treatment of moderate and severe cancer pain［J］.China Practical Medicine,2016,11(23):3-5.
［15］Yang P,Wang K.Oxycodone hydrochloride prolonged-release tablets for the treatment of cancer pain titration［J］.Chinese Journal of Oncology,2015,42(12):600-602.［杨平,王昆.盐酸羟考酮缓释片用于癌痛治疗的滴定［J］.中国肿瘤临床,2015,42(12):600-602.］
［16］O'Mahony S,Goulet J,Kornblith A,et al.Desire for hastened death,cancer pain and depression:Report of a longitudinal observational study［J］.Journal of Pain & Symptom Management,2005,29(5):446-457.
［17］Matsuoka H,Makimura C,Koyama A,et al.Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin［J］.Anticancer Research,2012,32(5):1805-1809.
［18］Arai YC,Matsubara T,Shimo K,et al.Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine［J］.Journal of Anesthesia,2010,24(3):407-410.
［19］Dong L,Sun HP.Efficacy of fluoxetine in the treatment of pain and depression in patients with malignant tumor［J］.Jilin Medical University,2013,34(31):6440-6442.［董磊,孙红培.盐酸氟西汀减轻恶性肿瘤患者疼痛及抑郁状态的疗效观察［J］.吉林医学,2013,34(31):6440-6442.］
［20］Huang GL,Huang Y,Li YJ,et al.Clinical effect of rehabilitation training combined with flupentixol and melitracen tablets in treatement of post stroke depression［J］.China Medicine & Pharmacy,2016,6(20):167-169.
［21］Tang J,Chen J,Tan Y,et al.A clinical comparative study of flupentixol and melitracen tablets in treatment of refractory functional dyspepsia［J］.Chinese Journal of Clinical Gastroenterology,2016,28(1):16-19.
［22］Wu MH,Zhou YF,Lou J,et al.Morphine sulfate sustained release tablets combined with flupentixol and melitracen tablets in the treatment for 22 cases with cancer pain［J］.Journal of Chinese Oncology,2011,17(7):542-545.
［23］Zou FY,Guan W,Wan JY.The application of flupentixol/melitracen combined with morphine sulfate for the treatment of severe cancer pain in 38 cases［J］.Journal of Jiangxi University of Traditional Chinese Medicine,2014,26(6):21-23.［邹方友,官炜,万基勇.黛力新联合美施康定治疗重度癌痛38例［J］.江西中医药大学学报,2014,26(6):21-23.］

Memo

Memo:
National Natural Science Foundation of China（No.81602597）；国家自然科学基金青年项目(编号：81602597)
Last Update: 2017-12-29